Divarasib

A selective, oral, investigational molecule

Divarasib is a selective, oral, investigational molecule designed to target KRAS G12C, a driver mutation in cancer

G12C=glycine-to-cysteine substitution at codon 12; KRAS=Kirsten rat sarcoma viral oncogene homolog.